ANCHORED RSK3 INHIBITORS, LLC
AAV gene therapy vector expressing RSK3 anchoring disruptor peptide to prevent pathological cardiac remodeling and heart failure
- Sector
- Biotech
- Total capital
- $299K
- Federal grants
- $299K
- 1 award · 2015
- Rank in peer group#66 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 6
- 1 pending · first 2015
- Rank in peer group#20 of 392
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · RSK3 Anchoring Disruptor Therapy for Heart Failure$299K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#66 · top 17%
- Granted patents#20 · top 5%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 6 granted of 7- New patentCOMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaUSPTOUS 12,758,611
- PendingCOMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaUSPTOApplication 18432983
- GrantedCOMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaUSPTOUS 11,931,402
Show all 7 patent records
- COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaOct 13, 2026 · US 12,758,611Granted
- COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaJul 4, 2024 · Application 18432983Pending
- COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaMar 19, 2024 · US 11,931,402Granted
- COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-betaJan 25, 2022 · US 11,229,679Granted
- COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-ßApr 14, 2020 · US 10,617,737Granted
- TREATMENT OF MYOCARDIAL INFARCTION BY INHIBITING THE ACTION OF mAKAPßApr 10, 2018 · US 9,937,228Granted
- Treatment Of Heart Disease By Inhibition Of The Action Of Ribosomal S6 Kinase 3 (RSK3)Sep 15, 2015 · US 9,132,174Granted
Related companies, and why
- NITRO BIOSCIENCES INC.Similar federal contract value in Biotech · null in contracts
- CADRE BIOSCIENCE, LLCSimilar federal contract value in Biotech · null in contracts
- WALIA, RAMPYARISimilar federal contract value in Biotech · null in contracts
- KARIVEZ, LLCSimilar federal contract value in Biotech · null in contracts
- NOVO HEAL, INC.Similar federal contract value in Biotech · null in contracts
- Character BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .